Sexually transmitted diseases (STDs) are a major health problem for adolescents. The highest rates of gonorrhea and chlamydia are reported for adolescents and young adults [1] . Providers of health care for adolescents play a critical role in preventing and treating STDs. To assist providers with their efforts, in May 2002 the Centers for Disease Control and Prevention (CDC) published the Sexually Transmitted Diseases Treatment Guidelines 2002 [2••] . These evidence-based guidelines for the treatment of patients who have STDs are based on a systematic literature review focusing on new information published since the 1998 Guidelines for Treatment of Sexually Transmitted Diseases [3] .
Although the revised 2002 guidelines emphasize treatment, they also discuss prevention strategies and diagnostic recommendations. This article summarizes what is new in the revised CDC STD treatment guidelines.
Treatment recommendations Chlamydia
The recommended treatment regimen for uncomplicated genital chlamydia infection remains unchanged from the 1998 guidelines. The CDC recommend either azithromycin, 1 g in a single oral dose, or doxycycline, 100 mg orally twice a day for 7 days. Although the results of clinical trials indicate that azithromycin and doxycycline are equally efficacious [4] [5] [6] [7] [8] , singe-dose treatment can maximize compliance.
To maximize compliance with recommended regimens, medications for chlamydial infections should be dispensed on-site, and the patient should be directly observed taking the first dose. To minimize further transmission and reinfection, patients should be instructed to abstain from sexual intercourse for 7 days after singledose therapy or until completion of a 7-day regimen and should also be instructed to abstain from sexual intercourse until all of their sex partners have been treated.
Longitudinal studies of chlamydia-infected adolescent female patients demonstrate a high risk for chlamydia reinfection and other STD infection within a few months of initial diagnosis [9] [10] [11] [12] . Because of the high incidence of chlamydia infection that can occur in the months following a treated infection, the guidelines suggest that providers consider repeat screening chlamydia-infected female patients 3 to 4 months after treatment.
Gonorrhea
Although uncomplicated genital gonorrhea infections can be treated with single-dose therapy (Table 1) [2••], there are fewer oral treatment options. Because of the recent emergence of quinolone-resistant Neisseria gonorrhoeae in California, Hawaii, Asia, and the Pacific islands, quinolones should not be used to treat gonorrhea infections acquired in these areas or in areas with an increased prevalence of quinolone resistance [13] . Fluoroquinolones have not been recommended for persons younger than 18 years because irreversible articular cartilage damage has developed in juvenile animals treated with very high doses of fluoroquinolones. However, no permanent joint damage attributable to therapy has ever been reported in fluoroquinolone-treated children [14•]. Therefore, children weighing 45 kg or more can be treated with any adult recommended regimen.
In July 2002, Wyeth Pharmaceuticals (Collegeville, PA) discontinued manufacturing cefixime (Suprax*) in the United States [15] . In the United States, no other pharmaceutical company manufactures or sells cefixime tablets. In the absence of cefixime, the primary recommended treatment option for gonorrhea in Hawaii and California is ceftriaxone [16••] . A description of oral cefixime alternatives for uncomplicated urogenital gonorrhea infections is available at the CDC Division of STD Prevention's web site at http://www.cdc. gov/std/treatment/Cefixime.htm.
Adolescents infected with N. gonorrhoeae often are coinfected with Chlamydia trachomatis. Because treatment of chlamydia infection can be less expensive than testing for chlamydia, the CDC have recommended empirically treating patients with positive gonorrhea test results for both gonorrhea and chlamydia [3] . In some areas where chlamydia coinfection rates are low, however, providers may choose to treat only those gonorrhea-infected patients with a negative chlamydia nucleic acid amplification test result [2••,17••] . Providers can consult with their local health department to ascertain the proportion of gonococcal infections that are accompanied by chlamydia infection in their community.
Bacterial vaginosis
In female patients reporting vaginal discharge, bacterial vaginosis is diagnosed by documenting the presence of at least three of the four Amsel criteria (thin, homogeneous, white, uniformly adherent vaginal discharge; vaginal pH > 4.5; positive "whiff" test; and >20% "clue" cells on microscopic examination). However, new commercial diagnostic tests for bacterial vaginosis are available that may be clinically useful. The Affirm VP III Microbial Identification Test (Becton Dickinson, Sparks, MD), is a DNA probe for the etiologic diagnosis of vaginitis: bacterial vaginosis, candidiasis, and trichomoniasis. The FemExam pH and Amines Test Card (Cooper Surgical, Shelton, CT) changes color in the presence of elevated vaginal pH and trimethylamines. The PIP Activity Test Card (Litmus Concepts, Inc., Santa Clara, CA) changes color in the presence of an enzyme expressed by Gardnerella vaginalis.
The goal in the treatment of bacterial vaginosis is to decrease vaginal symptoms and signs and to reduce the risk of associated infectious complications. Treatment of bacterial vaginosis is recommended for symptomatic females. Recommended regimen options include either metronidazole 500 mg orally twice daily for 7 days, clindamycin cream 2%, one full applicator (5 g) intravaginally once a day for 7 days [18••], or metronidazole gel 0.75%, one full applicator (5g) intravaginally now recommended for once a day dosing for 5 days. A new alternative treatment regimen is clindamycin ovules 100 g intravaginally at bedtime for 3 days. Metronidazole 2 g orally in a single dose and clindamycin 300 mg orally twice a day for 7 days are other treatment options [2••]. Because of metronidazole's disulfiram-like effect, abstinence from alcohol during and for 24 hours after therapy should be stressed. Clindamycin cream and ovules are oil-based and should not be used with latex barrier contraceptives.
Trichomoniasis
Traditionally, trichomoniasis is diagnosed by microscopic visualization of the characteristic erratic twirling motion of the organism's flagella on a wet preparation of vaginal fluid, but this diagnostic test has a poor sensitivity. The Trichomonas vaginalis culture kit InPouch TV Culture (BioMed Diagnostics, San Jose, CA) is twice as sensitive as the traditional microscopic examination of vaginal fluid [19] . The InPouch TV Culture is approved by the Food and Drug Administration (FDA) and consists of a self-contained bag into which a female vaginal fluid specimen or a male first-void urine specimen can be *Use of trademark names is for identification purposes only and does not constitute endorsement by the federal government. inoculated. This can be done in the office setting, and the specimen can be viewed under the microscope like a wet preparation. If no trichomonads are seen, the bag can be hung vertically for 15 minutes, to allow any trichomonads to concentrate on the bottom of the bag, and then reexamined. If trichomonads are still not seen, the specimen can be cultured and reexamined daily via microscopy for up to 5 days. Although a nucleic acid amplification test for trichomonas has the potential to further enhance diagnostic sensitivity [19] , none is currently approved by the Food and Drug Administration for clinical use.
Although metronidazole 2 g orally in a single dose remains the recommended T. vaginalis treatment, metronidazole resistance can occur. If treatment failure occurs in a compliant patient who was not reinfected by an untreated partner, the patient should be retreated with metronidazole 500 mg twice a day for 7 days. If treatment failure occurs again, the patient should be treated with metronidazole 2 g once a day for 3 to 5 days. Patients with laboratory-documented infection who do not respond to the 3-to 5-day high-dose metronidazole regimen and who have not been reinfected should be managed with specialist consultation and determination of the T. vaginalis metronidazole-susceptibility. Consultation is available from CDC (phone: 770-488-4115 or website: http://www.cdc.gov/std/).
Vulvovaginal candidiasis
Although vulvovaginal candidiasis is not sexually transmitted, the STD treatment guidelines include vulvovaginal candidiasis diagnosis and management recommendations. In the 2002 guidelines, vulvovaginal candidiasis is classified into complicated and uncomplicated ( For complicated vulvovaginal candidiasis, such as recurrent, severe, nonalbicans cases or infections occurring in patients with altered immunity or pregnancy (see Table 2 ), acute therapy of longer duration may be needed to achieve mycologic remission. Acute therapy regimens include topical azole for 7 to 10 days or fluconazole 150 mg orally on day 1 and repeated 3 days later. Recurrent vulvovaginal candidiasis, defined as four or more episodes of symptomatic vulvovaginal candidiasis per year, should be managed with at least 6 months of maintenance therapy after the patient has completed a course of acute therapy. Recommended maintenance regimens include clotrimazole 500 mg vaginal suppositories once weekly; ketoconazole 100 mg once daily; fluconazole 100 to 150 mg once weekly; and itraconazole 400 mg once monthly or 100 mg once daily. Maintenance therapy should be discontinued after 6 months and patients should be reevaluated regarding their need for chronic medication.
Pelvic inflammatory disease
A diagnosis of pelvic inflammatory disease (PID) is usually based on clinical findings. However, making the diagnosis can be difficult because acute PID symptoms and signs vary widely and are often subtle or mild. The CDC's new PID diagnostic guidelines improve both the sensitivity and specificity of this challenging clinical diagnosis. To enhance sensitivity, the minimum criteria were expanded to "uterine or adnexal tenderness or cervical motion tenderness" (Table 3) . Empiric PID treatment should be initiated in sexually active young female patients if these minimum criteria are present and no other cause for the illness can be identified. To enhance the specificity of the minimum criteria and to avoid in- correct diagnosis and management, more elaborate diagnostic criteria are often needed to support a PID diagnosis (see Table 3 ).
Results from the PEACH study indicate that most women with PID have mucopurulent cervical discharge or evidence of white blood cells on a wet preparation of vaginal fluid [20] . Therefore, if the cervical discharge appears normal and no white blood cells are noted on wet preparation, the diagnosis of PID is unlikely and alternative causes of pain should be sought.
The significant changes in recommendations for treatment of PID are as follows: (1) levofloxacin 500 mg orally once daily for 14 days can be substituted for ofloxacin;
(2) metronidazole 500 mg twice a day for 14 days can also be used to enhance anaerobic coverage [21] ; and (3) the ciprofloxacin plus doxycycline plus metronidazole alternative parenteral treatment regimen is no longer recommended. Table 4 gives the current CDC recommendations for PID treatment regimens.
Genital herpes simplex virus
Since publication of the 1998 STD treatment guidelines, new accurate type-specific assays for herpes simplex virus (HSV) antibodies have become available. These assays differentiate between the HSV-specific glycoprotein G2 for the diagnosis of HSV-2 infection and glycoprotein G1 for the diagnosis of HSV-1 infection [22•].
Since the older type-specific HSV serologic assays do not accurately distinguish HSV-1 from HSV-2 antibody, the type-specific glycoprotein G-based assays should be specifically requested.
Currently, the glycoprotein G-based type-specific assays that are approved by the Food and Drug Administration include POCkit HSV-2 (Diagnology, Cary, NC), which detect HSV-2 antibodies during a clinic visit, and Herpe-Select-1 ELISA IgG, HerpeSelect-2 ELISA IgG, and HerpeSelect 1 and 2 Immunoblot IgG (Focus Technol-ogy, Inc., Cypress, CA) assays. The sensitivities of these serologic tests to detect HSV-2 antibody vary from 80 to 98%. False-negative results may occur, especially during the early stages of infection. The specificities of these assays are 96% or greater.
Because false-negative HSV culture findings are common, especially in patients with recurrent infection or with healing lesions, type-specific serologic tests may be used in confirming a clinical diagnosis of genital herpes. Additionally, these tests can be used to diagnose unrecognized infection and to manage the sex partners of persons with genital herpes. Although serologic assays for HSV-2 should be available for persons who request them, screening the general population for HSV-1 or HSV-2 infection is not recommended.
A new recommended treatment option for recurrent genital herpes episodes is valacyclovir 500 mg twice a day for 3 to 5 days. A 3-day course of valacyclovir is as effective as a 5-day course. An expanded HSV counseling section offers providers recommendations on natural history, treatment, transmission, disclosure, and prevention messages.
Syphilis
The revised 2002 STD treatment guidelines offer some new primary and secondary syphilis treatment options for penicillin-allergic patients. Limited studies suggest that ceftriaxone is effective for primary, secondary, or early latent syphilis treatment [23, 24] . Although the optimal ceftriaxone dosage and duration of treatment have not been defined, some specialists recommend 1 g daily, intramuscularly or intravenously, for 8 to 10 days. Preliminary data also suggest that azithromycin may be ef- fective as a single oral 2 g dose [24, 25] . Because the efficacy of these therapies is not well documented, close follow-up of persons receiving these therapies is essential. Since these therapies have not been studied in HIVinfected persons, their use of among such persons must be undertaken with caution [24] .
Congenital syphilis evaluation and management recommendations have expanded. The revised 2002 STD treatment guidelines present various clinical scenarios for the presentation of congenital syphilis; diagnosis, treatment, and follow-up for each scenario are discussed.
Genital warts
The revised 2002 guidelines include a new human papillomavirus (HPV) counseling section with recommendations for education and counseling messages regarding HPV. The guidelines recommend that patients with genital warts be made aware of that (1) HPV is common among sexually active individuals, (2) the incubation period can be long and variable, (3) recurrence of warts is common, and (4) duration of infection and methods of prevention of infection are not definitely known. Examples of educational messages and information about other patient-education materials are provided in the guidelines.
Despite limited data evaluating podofilox and imiquimod as treatment for distal meatal warts, some specialists recommend using these agents in certain patients. The 2002 STD treatment guidelines eliminate podophyllum resin as a treatment option for vaginal warts.
Since no definitive evidence suggests that any one available treatment is superior to another, and no single treatment is ideal for all patients or all warts, the guidelines recommend that treatment of genital warts be guided by patient preference, available resources, and health care provider experience [26••] . The use of locally developed and monitored treatment algorithms has been associated with improved clinical outcomes and should be encouraged. Because of uncertainty regarding the effect of treatment on future transmission and the possibility for spontaneous resolution, an acceptable alternative for some patients is foregoing treatment and awaiting spontaneous resolution [26••] .
Scabies
A simple alternative to topical scabies treatment is ivermectin 200 µg/kg orally in a single dose, repeated in 2 weeks. Studies have found that two doses of ivermectin have cure rates comparable to those of topical permethrin and lindane [27••] . This option may be more acceptable and easier to use than creams and lotions that must be applied to almost the entire body overnight.
Prevention
The 2002 guidelines provide adolescent-focused STD epidemiologic, clinical, and prevention information. The guidelines underscore that rates of many STDs are highest among adolescents, especially younger sexually active adolescents. Since all adolescents in the United States can consent to the confidential STD diagnosis and treatment and medical care for STDs can be provided to adolescents without parental consent or knowledge, during clinical encounters providers should inquire about sexual behavior, assess STD risk, counsel about risk reduction, and screen for asymptomatic infection. The guidelines stress that care and counseling should be developmentally appropriate, direct, and nonjudgmental.
Because nonoxynol-9 is not effective in preventing gonorrhea, chlamydia, or HIV and has been found to be associated with an increased risk for HIV infection [28] , the revised 2002 STD treatment guidelines do not recommend the routine use of nonoxynol-9 as a prevention strategy. However, client-centered counseling, described in the Revised Guidelines for HIV Counseling, Testing, and Referral [29••] , has been demonstrated to be effective in reducing incident STDs, especially among adolescents [30] .
Other changes to the treatment guidelines
In the 2002 STD treatment guidelines, the clinical approach to the pediatric victim of sexual assault has expanded. The revised guidelines recommend specific evaluations, treatments, and follow-up of alleged victims and address the social significance and recommended actions regarding STD reporting of suspected child victims of sexual abuse. New recommendations are provided for vaccine-preventable STDs, including hepatitis A and hepatitis B. Hepatitis C is presented as a sexually transmitted infection. The specifics of these recommendations are beyond the scope of this article.
Resources
The complete Sexually Transmitted Diseases Treatment Guidelines 2002 are available at http://www.cdc. gov/std/treatment/default.htm. Hard copies of the guide- 
Conclusion
Half of all U.S. high school students are sexually experienced [32] . The simple question, "Have you ever had sexual intercourse?" will identify many of the adolescent patients in need of reproductive health services. Female adolescents experience some of the highest rates of most STDs [1] . Most adolescents with STDs, regardless of pathogen, are asymptomatic. A primary care visit presents the perfect opportunity to screen for STDs. Health care providers who see adolescents are in a good position to implement effective STD and HIV control through risk assessment, disease screening, and CDCrecommended treatment and prevention counseling.
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